AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTAbbott said total net sales rose 7.5% in Q2 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $102 million in Q2, compared with $263 million a year earlier. Excluding those sales, total net sales increased 5.7%.
Key points
AI summaryAbbott said total net sales rose 7.5% in Q2 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $102 million in Q2, compared with $263 million a year earlier. Excluding those sales, total net sales increased 5.7%.
The company said Medical Devices sales in the first six months of 2024 rose 13.8% excluding the impact of foreign exchange. FreeStyle Libre sales totaled $3.0 billion in the period, compared with $2.5 billion a year earlier, an increase of 21.8% excluding the effect of foreign exchange.
Abbott said other income, net fell from $176 million of income in Q2 2023 to $10 million of expense in Q2 2024. The company cited a $143 million loss recognized in the second quarter on the sale of a non-core business in the Established Pharmaceutical Products segment as a factor in the decrease.
The company said it received from the IRS a SNOD for the 2017 and 2018 Federal tax years in June 2024 in the amount of $192 million, and a RAR assessing additional income tax of $443 million for the 2020 tax year. The company said the income reallocation adjustments are without merit and that it is contesting them and intends to vigorously defend its filing positions.
Key figures
Quarter ended June 30, 2024
- Revenue
- $10.4B
- Operating income
- $1.7B
- Net income
- $1.3B
- EPS
- $0.74
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 2024 Net Sales Growth and COVID-19 Testing Sales
Abbott said total net sales rose 7.5% in Q2 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $102 million in Q2, compared with $263 million a year earlier. Excluding those sales, total net sales increased 5.7%.
Source · Based on the MD&A text of the filing
2024 First-Half Medical Devices Sales and FreeStyle Libre
The company said Medical Devices sales in the first six months of 2024 rose 13.8% excluding the impact of foreign exchange. FreeStyle Libre sales totaled $3.0 billion in the period, compared with $2.5 billion a year earlier, an increase of 21.8% excluding the effect of foreign exchange.
Source · Based on the MD&A text of the filing
Q2 2024 Other Income Decline and Non-Core Business Sale Loss
Abbott said other income, net fell from $176 million of income in Q2 2023 to $10 million of expense in Q2 2024. The company cited a $143 million loss recognized in the second quarter on the sale of a non-core business in the Established Pharmaceutical Products segment as a factor in the decrease.
Source · Based on the MD&A text of the filing
IRS Notices and Reports and Abbott’s Response
The company said it received from the IRS a SNOD for the 2017 and 2018 Federal tax years in June 2024 in the amount of $192 million, and a RAR assessing additional income tax of $443 million for the 2020 tax year. The company said the income reallocation adjustments are without merit and that it is contesting them and intends to vigorously defend its filing positions.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…